168 related articles for article (PubMed ID: 8666367)
1. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.
Wertz IE; Deitch AD; Gumerlock PH; Gandour-Edwards R; Chi SG; de Vere White RW
Hum Pathol; 1996 Jun; 27(6):573-80. PubMed ID: 8666367
[TBL] [Abstract][Full Text] [Related]
2. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.
Schlechte H; Lenk SV; Löning T; Schnorr D; Rudolph BD; Ditscherlein G; Loening SA
Eur Urol; 1998; 34(5):433-40. PubMed ID: 9803007
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.
Yaman O; Ozdiler E; Orhan D; Sak SD; Baltaci S; Tulunay O; Göğüş O
Urol Int; 1997; 58(4):199-202. PubMed ID: 9253117
[TBL] [Abstract][Full Text] [Related]
4. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
5. Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of
Guedes LB; Almutairi F; Haffner MC; Rajoria G; Liu Z; Klimek S; Zoino R; Yousefi K; Sharma R; De Marzo AM; Netto GJ; Isaacs WB; Ross AE; Schaeffer EM; Lotan TL
Clin Cancer Res; 2017 Aug; 23(16):4693-4703. PubMed ID: 28446506
[No Abstract] [Full Text] [Related]
6. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
[TBL] [Abstract][Full Text] [Related]
7. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
8. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
9. Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer.
Uchida T; Wada C; Shitara T; Egawa S; Koshiba K
Br J Cancer; 1993 Oct; 68(4):751-5. PubMed ID: 7691145
[TBL] [Abstract][Full Text] [Related]
10. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.
Meyers FJ; Gumerlock PH; Chi SG; Borchers H; Deitch AD; deVere White RW
Cancer; 1998 Dec; 83(12):2534-9. PubMed ID: 9874460
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
12. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
[TBL] [Abstract][Full Text] [Related]
13. Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay.
Shi XB; Bodner SM; deVere White RW; Gumerlock PH
Diagn Mol Pathol; 1996 Dec; 5(4):271-8. PubMed ID: 8955619
[TBL] [Abstract][Full Text] [Related]
14. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
[TBL] [Abstract][Full Text] [Related]
15. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations.
Mottaz AE; Markwalder R; Fey MF; Klima I; Merz VW; Thalmann GN; Ball RK; Studer UE
Prostate; 1997 Jun; 31(4):209-15. PubMed ID: 9180930
[TBL] [Abstract][Full Text] [Related]
16. Alteration of the p53 locus in benign hyperplastic prostatic epithelium associated with high-grade prostatic adenocarcinoma.
Kallakury BV; Jennings TA; Ross JS; Breese K; Figge HL; Fisher HA; Figge J
Diagn Mol Pathol; 1994 Dec; 3(4):227-32. PubMed ID: 7532528
[TBL] [Abstract][Full Text] [Related]
17. p53 oncogene mutations in human prostate cancer specimens.
Voeller HJ; Sugars LY; Pretlow T; Gelmann EP
J Urol; 1994 Feb; 151(2):492-5. PubMed ID: 7904314
[TBL] [Abstract][Full Text] [Related]
18. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia.
Thompson SJ; Mellon K; Charlton RG; Marsh C; Robinson M; Neal DE
Br J Urol; 1992 Jun; 69(6):609-13. PubMed ID: 1379102
[TBL] [Abstract][Full Text] [Related]
19. Frequency and characterization of p53 mutations in clinically localized prostate cancer.
Hall MC; Navone NM; Troncoso P; Pollack A; Zagars GK; von Eschenbach AC; Conti CJ; Chung LW
Urology; 1995 Mar; 45(3):470-5. PubMed ID: 7879337
[TBL] [Abstract][Full Text] [Related]
20. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
